Oncology & Cancer

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

(HealthDay)—For frail and elderly patients with advanced gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a study presented at the ...

Oncology & Cancer

POLO trial for advanced pancreatic cancer: a new standard of care

Treatment with the drug olaparib significantly reduced the risk of disease progression or death from metastatic pancreatic cancer, according to findings from the recently completed, international, phase-III POLO (Pancreas ...

Oncology & Cancer

Entrectinib gets edge over crizotinib against ROS1+ lung cancer

Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials are created equal, and ...

Oncology & Cancer

ASCO: Low-fat dietary pattern cuts breast cancer deaths

(HealthDay)—A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up, according to a study scheduled to ...

Health

Clinical guidelines from specialty societies often biased

Clinical practice guidelines issued by specialty societies in North America often recommend health care services linked to their specialties, in contrast with European guidelines and those from independent organizations, ...

page 10 from 38